Neurocrine fleshes out its PhIII case for valbenazine; Avrobio adds to gene therapy pipeline – Endpoints News
|
Neurocrine fleshes out its PhIII case for valbenazine; Avrobio adds to gene therapy pipeline
Endpoints News The PDUFA date for the breakthrough therapy is April 11. → Cambridge, MA-based biotech Avrobio is expanding its gene therapy pipeline. Investigators are adding a preclinical program for Gaucher disease, which will follow their Phase I for Fabry disease. |
